Nimorazole (INN) is a nitroimidazole anti-infective.[1] It is also being investigated for the treatment of head and neck cancer.[2][3]
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.026.723 |
Chemical and physical data | |
Formula | C9H14N4O3 |
Molar mass | 226.236 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
References
edit- ^ Roy RB, Laird SM, Heasman L (August 1975). "Treatment of trichomoniasis in the female. A comparison of metronidazole and nimorazole". The British Journal of Venereal Diseases. 51 (4): 281–4. doi:10.1136/sti.51.4.281. PMC 1046566. PMID 1098732.
- ^ Henk JM, Bishop K, Shepherd SF (January 2003). "Treatment of head and neck cancer with CHART and nimorazole: phase II study". Radiotherapy and Oncology. 66 (1): 65–70. doi:10.1016/S0167-8140(02)00284-0. PMID 12559522.
- ^ Clinical trial number NCT01507467 for "IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck" at ClinicalTrials.gov